Financial Performance - Q2 FY27

  • Total Income: ₹100.57 crore (₹1,005.7 million) compared to ₹79.58 crore in Q2 FY26, representing 26.4% YoY growth
  • EBITDA: ₹36.32 crore compared to ₹24.97 crore in Q2 FY26
  • EBITDA Margin: 36.7% compared to 31.7% in corresponding quarter
  • PAT: ₹14.95 crore compared to ₹8.828 crore in Q2 FY26, representing 69% YoY growth
  • PAT Margin: 15.1%

Operational Metrics - Q2 FY27

  • Patients Served: 0.42 million
  • Tests Performed: 2.4 million (corrected from 2.32 million mentioned in press release)
  • Tests Per Patient: 5.7
  • Revenue Per Patient: ₹2,348
  • EBITDA Per Patient: ₹861

Financial Performance - H1 FY27

  • Total Income: ₹189.31 crore (₹1,893.1 million) compared to ₹153.07 crore in H1 FY26, representing 23.7% YoY growth
  • EBITDA: ₹67.85 crore compared to ₹49.62 crore in H1 FY26
  • EBITDA Margin: 36.3%
  • PAT: ₹27.796 crore compared to ₹18.00 crore in H1 FY26, representing 54% YoY growth
  • PAT Margin: 14.9%

Operational Metrics - H1 FY27

  • Patients Served: 0.8 million
  • Tests Performed: 4.5 million
  • Tests Per Patient: 5.63
  • Revenue Per Patient: ₹2,335
  • EBITDA Per Patient: ₹849

Network Expansion and Center Performance

  • Total Centers: 77 centers at end of September 30, 2026
  • New Centers Added in Q2: 5 centers, marking entry into Jharkhand
  • Tripura Expansion: Infrastructure and equipment installation underway, operations expected to commence in second half of FY27
  • Mature Centers (more than 2 years old): Delivered 42% EBITDA margin in Q2 FY27
  • Centers under 2 years old: Improved to 11.8% EBITDA margin from negative 16.8% in corresponding period last year
  • Centers more than 1 year old: Estimated margin around 30%

Geographical Revenue Mix - H1 FY27

  • Greater Kolkata: 67% of revenues
  • Rest of Bengal: 29% of revenues
  • Other Regions: 4% of revenues

Business Segments and Initiatives

Genomics Division:

  • Focus areas: Prenatal diagnostics, inherited diseases, pharmacogenomics, oncology-focused molecular panels
  • Exploring advanced areas: Whole genome testing, metagenomics, AI integration
  • Currently small vertical but considered promising for future growth
  • East India described as "very underpenetrated market" for genomics

Strategic Collaborations:

  • Asian Institute of Immunology and Rheumatology: Partnership for autoimmune diseases services
  • Fetomat: Fetal medicine unit acquisition adding to prenatal diagnostics and genomic lab

Home Collection Services:

  • Contributes approximately 10% of total revenues
  • Expanding to newer geographies

B2B/Institutional Segment:

  • Focus on holistic service platform to command marginally higher rates than competition
  • Genomics expected to add to B2B business

Management Commentary and Guidance

Expansion Strategy:

  • Target: 100 centers by end of FY28
  • Post-FY28 expansion: 5-10 centers annually at slower pace
  • Approach: Concentric expansion to minimize gestation period, cluster-based development

Margin Outlook:

  • Steady-state margin for FY28 expected: 34-35%
  • Mature centers expected to sustain around 42% margin
  • Corporate costs include employee costs, marketing expense, and IT expense

Revenue Guidance:

  • Committed to 15-18% annual growth
  • Q3 FY27 expected to be muted due to festive season (Durga Puja, Diwali)
  • Q4 typically stronger than Q3

Revenue Per Patient Outlook:

  • Expected to hover around current levels (₹2,300-₹2,400)
  • Growth drivers: Patient footfall increase rather than price hikes
  • B2B business growth may limit revenue per patient increase

Cost Structure

  • Depreciation and finance cost increase in Q2 FY27 due to new centers and lease agreements under IndAS 116
  • Gross margin improved by 1% in quarter due to inventory consumption and reporting doctor fees
  • Hub-and-spoke model used to maximize utilization of expensive equipment (MRI, CT scanners)

Competitive Positioning

  • Integrated model (pathology, radiology, medical consultations) provides competitive advantage
  • Focus on convenience and one-stop shop for patients
  • Trust-based business with familiarity driving patient retention

Acquisition Strategy

  • Evaluation parameters: Quality of asset, valuation, growth potential
  • Preference for comprehensive diagnostics (radiology and pathology combined)
  • Focus on assets that fill geographic gaps in current setup